Figure 6.

The DCN-AGER pathway drives antitumor immunity induced by vaccination with ferroptotic cancer cells. (A) The inhibition of DCN and AGER (but not TLR4) with specific blocking antibodies (Ab; 20 mg/kg) abolished the capacity of RSL3-treated tumor cells to vaccinate against KPC cells in C57BL/6 J mice. The percentage of tumor-free mice is indicated (n = 10 mice/group, *P < 0.05, two-way ANOVA test). (B) The inhibition of TLR4 (but not DCN or AGER) with specific blocking antibodies (20 mg/kg) abolished the capacity of oxaliplatin-treated tumor cells to vaccinate against KPC cells in C57BL/6 J mice. The percentage of tumor-free mice is indicated (n = 10 mice/group, *P < 0.05, two-way ANOVA test). (C) The vaccination effect of RSL3-induced ferroptotic cell death in KPC cells was not observed in immune-deficient (rag2^−/−) mice (n = 10 mice/group).